Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vicriviroc in Treatment-Experienced HIV-Infected Patients
NCT00082498Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2004
- Primary completion
- Dec 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vicriviroc in human immunodeficiency virus infection (HIV) (4 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Change in HIV-1 viral load at Day 14. Started May 2004; status: completed.
02
Drugs
vicriviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00082498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082498.